Rhizen Pharmaceuticals

Rhizen Pharmaceuticals is a private, clinical-stage biotech company developing novel small molecule therapeutics for oncology and inflammation. The company has a pipeline with assets in Phase 1 and Phase 2 clinical trials, including Tenalisib for metastatic triple-negative breast cancer (TNBC) and RP12146 for metastatic castration-resistant prostate cancer (mCRPC). Rhizen operates with a capital-efficient model, aiming to progress assets to clinical proof-of-concept before out-licensing to global partners for registration and commercialization. The company emphasizes full intellectual property ownership of its programs.

Focus on discovery and development of novel small molecule therapeutics targeting multiple hallmarks of cancer and inflammation. Emphasizes 100% IP ownership and a biology-driven approach.

Rhizen competes in highly competitive spaces. In TNBC, competitors range from chemotherapies to PARP inhibitors and immunotherapies. The mCRPC landscape features advanced hormonal agents, chemotherapies, and radiopharmaceuticals. Differentiation through novel mechanisms, efficacy, or safety profiles is critical for success.